Single award · contract
Treatment for Use in a Mass Casualty Event Where Thrombocytopenia or Platelet Loss Is a Major Concern
Award ID: 75A50122C00065
FY2022 · complete year · data as of 2026-07-11
A single federal award, with both ends of the trail linked.
$839.9M
Total award value
Award 75A50122C00065 is a contract from the Department of Health and Human Services to Amgen USA Inc, $839.9M obligated, FY2022 to FY2032, for Treatment for Use in a Mass Casualty Event Where Thrombocytopenia or Platelet Loss Is a Major…. The work is performed in California. It is classified as NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)) and PSC AN13 (Health R&D Services; Health Care Services; Experimental Development). Source
Agency ›
Department of Health and Human Services
Source
awarded→$839.9M
Recipient ›
Amgen USA Inc
Source
performed in→
Description
Treatment for Use in a Mass Casualty Event Where Thrombocytopenia or Platelet Loss Is a Major Concern.
Award details
Award typeContract
PIID75A50122C00065
Action date2022
Period120 mo
Awarding agencyDepartment of Health and Human Services →
RecipientAmgen USA Inc →
Place of performanceCalifornia →
CategoryNAICS 541714PSC AN13
Competed?Not recordedSource
Total (exact)$839,875,190
More from Department of Health and Human Services
awarded 2025$110.4B
awarded 2024$100.1B
awarded 2023$92B
awarded 2022$80.5B
awarded 2021$80.5B
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.